OR-AIRSHIP
7.4.2022 10:02:06 CEST | Business Wire | Press release
Airship , the mobile app experience company, today announced the launch of its App Experience Platform (AXP), the only enterprise SaaS platform focused on helping brands master the full lifecycle of mobile app experience (MAX) management. AXP aims to address the ongoing challenge for brands to treat their apps as a high-value destination rather than simply a promotional messaging channel.
Mobile apps have become the centre of the digital customer experience — generating more than three times greater revenue and transaction frequency compared to other channels. Yet, according to data derived from Apptopia, app user retention rates have barely increased over the last three years, despite ongoing growth in annual worldwide app downloads.
AXP enables product, digital and marketing teams to create, refine and publish no-code native app experiences on their own without ongoing developer support or app updates. As a result, it vastly improves the continuous onboarding, retention and first party and zero-party data collection of customers. This new SaaS platform also unifies the native app experiences, customer journey orchestration and app UX experimentation with no-code approaches and intuitive visual UIs, freeing development teams to innovate market-differentiating app features.
Brett Caine, CEO and President at Airship, said : “Messaging only goes so far in helping to retain and monetise app users. Brands must provide valuable and relevant experiences in the moments people are engaged with the app to create reciprocal value exchanges necessary for sustained relationships .” He added: “With AXP, we’re giving brands unparalleled agility to grow user understanding and provide app experiences that reward customers for their loyalty .”
More than 15 leading brands gained early access to new AXP innovations such as AXP Mobile Data Hub, AXP Scenes, AXP Surveys and AXP Preference Center to evaluate and test the benefit to their businesses and provide feedback for ongoing refinement.
Joseph Brooks, Head of Product, Shell plc, one of Airship’s customers, said: “The Shell app is the centrepiece of our customers’ mobility experience, allowing them to pay and save in one easy step. With Airship’s real-time notifications and in-app automation we’ve increased our retention rate 3X and grown our active user base by 3.5X . The new capabilities in Airship’s App Experience Platform will help to dramatically accelerate our time-to-market and agility in optimising user onboarding and collecting in-app feedback from users to continue to improve their app experience .”
Michael Lowe, Vice President, Digital Strategy & Partnerships at NBC Sports Group, another of Airship’s customers, added: “Sports fans demand the best, most personalised in-the-moment app experiences, and it’s a requirement for our teams to look for opportunities for continued innovation that facilitates new user onboarding, drives new feature adoption, introduces new content franchises, and elicits valuable user feedback. Airship’s App Experience Platform provides us with new capabilities that save valuable product development time and give our team faster ways to optimise each fan’s journey .”
According to Forrester Research, Inc.’s, August 2021 report “Make Marketing More Than A Message ”: “The best brand experiences connect to customers in critical moments, not just at a channel level. Pulling off this level of personalisation requires that brands design for moments first … Marketers are innovating across critical facets of business (not just with media and messaging) by shaping the entire experience to differentiate their brand in the eyes of their customers .”
For the latest information on consumer privacy attitudes, preferences and behaviours, and how brands can create a trusted exchange with their customers, register for an April 14th webinar featuring guest speaker Stephanie Liu, Analyst, Forrester Research, Inc., and Mike Herrick, SVP of Technology, Airship.
For more detail on this announcement, please access ungated eBooks on MAX and AXP .
Additional Customer Quotes:
“Our entire team was both surprised and delighted by Airship’s new App Experience Platform ,” said Laurent Claramonte, head of data analytics for Products and Mobile Apps at Orange France . “With more than 10 apps in total, including TV, Smart Home and Messaging apps like Orange TV or Orange Mail, new capabilities like AXP Scenes free our developers to focus on new innovations as our product owners now have full autonomy to continually optimise native, multi-screen experiences that drive feature adoption. AXP is a game-changer, allowing us to go far beyond promotional and messaging-based approaches to drive better app onboarding and retention, and achieve greater customer satisfaction and loyalty .”
“As the most popular football media platform in the world, OneFootball is constantly adding new features, products and content to provide an immersive and fully personalised experience to more than 100 million football fans monthly ,” said Ismail Elshareef, Chief Product Officer at OneFootball . “With AXP Scenes and Surveys we can provide fans with better onboarding to these new experiences, collect more information upfront for greater personalization, and better inform future development to ensure our customers get exactly what they want from OneFootball .”
About Airship
No one knows more, does more, or cares more when it comes to helping brands master mobile app experiences than Airship.
From the beginning of apps, Airship powered the first commercial messages and then expanded its data-led approach to all re-engagement channels (mobile wallet, SMS, email), app UX experimentation and feature release management. Now, with the Airship App Experience Platform (AXP), business users can create and adapt native app experiences on their own — with no ongoing developer support or app update required.
Having powered trillions of mobile app interactions for thousands of global brands, Airship’s technology and deep industry expertise have enabled apps to become the digital centre of customer experience, brand loyalty and monetisation.
For more information, visit www.airship.com , read our blog or follow us on Twitter , LinkedIn and Facebook .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220406006111/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom